Pembrolizumab enhances the immune system’s ability to fight HNSCC by blocking the PD-1/PD-L1 interaction, which can be effective even in rare metastatic sites like the duodenum. The gene discussed is CD274; the disease is head and neck squamous cell carcinoma.